Wall Street brokerages expect Spero Therapeutics Inc (NASDAQ:SPRO) to post earnings of ($0.78) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Spero Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.85) and the highest estimate coming in at ($0.71). Spero Therapeutics reported earnings of ($36.02) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 97.8%. The firm is scheduled to report its next earnings results on Thursday, December 13th.
According to Zacks, analysts expect that Spero Therapeutics will report full year earnings of ($3.20) per share for the current year, with EPS estimates ranging from ($3.85) to ($2.81). For the next financial year, analysts anticipate that the business will report earnings of ($3.73) per share, with EPS estimates ranging from ($4.30) to ($3.30). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Thursday, August 9th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.08. Spero Therapeutics had a negative net margin of 1,479.91% and a negative return on equity of 182.49%. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.62 million.
Several research analysts have commented on SPRO shares. Oppenheimer set a $30.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Monday, July 9th. Cantor Fitzgerald set a $27.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Monday, July 9th. HC Wainwright started coverage on shares of Spero Therapeutics in a report on Friday, May 11th. They set a “buy” rating and a $28.00 price target for the company. Finally, ValuEngine upgraded shares of Spero Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Spero Therapeutics has a consensus rating of “Buy” and an average price target of $25.00.
SPRO traded down $0.03 during trading hours on Friday, hitting $11.27. 68,672 shares of the company’s stock were exchanged, compared to its average volume of 230,178. Spero Therapeutics has a 12-month low of $9.66 and a 12-month high of $19.00. The company has a market cap of $162.37 million and a P/E ratio of -0.63.
In other news, CFO Joel Sendek sold 2,000 shares of the company’s stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $17.50, for a total value of $35,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Plc Glaxosmithkline bought 80,000 shares of the stock in a transaction dated Tuesday, July 17th. The stock was bought at an average price of $12.50 per share, with a total value of $1,000,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 10,676 shares of company stock valued at $187,438 in the last quarter. 26.90% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in Spero Therapeutics by 19,604.3% during the 1st quarter. JPMorgan Chase & Co. now owns 256,353 shares of the company’s stock worth $3,653,000 after purchasing an additional 255,052 shares during the period. BlackRock Inc. acquired a new stake in Spero Therapeutics during the 4th quarter worth $2,830,000. DAFNA Capital Management LLC boosted its stake in Spero Therapeutics by 490.9% during the 1st quarter. DAFNA Capital Management LLC now owns 29,544 shares of the company’s stock worth $421,000 after purchasing an additional 24,544 shares during the period. BVF Inc. IL boosted its stake in Spero Therapeutics by 1.9% during the 1st quarter. BVF Inc. IL now owns 1,048,958 shares of the company’s stock worth $14,948,000 after purchasing an additional 19,773 shares during the period. Finally, Deutsche Bank AG acquired a new stake in Spero Therapeutics during the 4th quarter worth $155,000. Institutional investors and hedge funds own 45.92% of the company’s stock.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Recommended Story: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.